window.pageData = {"stock":{"_id":3000000025173,"name":"德邦医疗创新混合型发起式证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","status":"normal","stockCode":"025173","tickerId":25173,"shortName":"德邦医疗创新混合发起式C","currency":"CNY","exchange":"jj","masterFundFlag":null,"indexFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"inceptionDate":"2025-08-28T16:00:00.000Z","pinyin":"dbylcxhhxfqszqtzjj","fundCollectionId":4000050710000,"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50710000","tickerId":50710000,"name":"德邦基金管理有限公司"},"managers":[{"name":"袁之渿","stockType":"fund_manager","stockCode":"j101020183","exchange":"fm","tickerId":252614256740}],"hotMetrics":{"fpr":{"stockId":3000000025173,"type":"fpr","f_cagr_p_r_fs_ssc":9107,"f_cagr_p_r_fs_ssrp":0.9991214583790907,"f_p_r_m1_ssc":9177,"f_p_r_m1_ssrp":0.5014167393199651,"f_p_r_m3_ssc":9037,"f_p_r_m3_ssrp":0.9737715803452855,"f_p_r_fys_ssc":9000,"f_p_r_fys_ssrp":0.9645516168463163,"f_p_r_m6_ssc":8759,"f_p_r_m6_ssrp":0.960949988581868},"fp":{"stockId":3000000025173,"type":"fp","last_data_date":"2026-04-23T16:00:00.000Z","f_cagr_p_r_fs":-0.20063757720661535,"f_p_r_m1":0.05648452929558956,"f_p_r_m3":-0.1561678409927435,"f_p_r_fys":-0.08034383954154711,"f_p_r_m6":-0.1020590868397494},"f_nlacan":{"stockId":3000000025173,"type":"f_nlacan","f_nv_d":"2026-04-23T16:00:00.000Z","f_nv":0.8024,"f_nv_cr":0.009435149075355254},"f_as":{"stockId":3000000025173,"type":"f_as","f_tas":13922271.5016,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000025172,"__csrcFundId":15577,"stockCode":"025172","masterFundShortName":"德邦医疗创新混合发起式","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":25172,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"德邦医疗创新混合发起式A","lastUpdated":"2025-09-12T18:05:56.865Z","name":"德邦医疗创新混合型发起式证券投资基金","pinyin":"dbylcxhhxfqszqtzjj","fundCollectionId":4000050710000,"setUpAssetScale":13106857.82,"setUpDate":"2025-08-25T16:00:00.000Z","setUpShares":13106857.82,"inceptionDate":"2025-08-28T16:00:00.000Z","followedNum":3}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000025172,"stockId":2821,"holdings":17100,"marketCap":1894167,"netValueRatio":0.0763,"quarterlyChange":0.19197245238351623,"stock":{"stockCode":"002821","exchange":"sz","stockType":"company","tickerId":2821,"name":"凯莱英"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000025172,"stockId":603259,"holdings":18200,"marketCap":1785420,"netValueRatio":0.0719,"quarterlyChange":0.08230361871138547,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000025172,"stockId":300677,"holdings":30400,"marketCap":1783872,"netValueRatio":0.0718,"quarterlyChange":0.5084832904884322,"stock":{"stockCode":"300677","exchange":"sz","stockType":"company","tickerId":300677,"name":"英科医疗"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000025172,"stockId":300759,"holdings":60200,"marketCap":1684396,"netValueRatio":0.0678,"quarterlyChange":-0.015828350334153862,"stock":{"stockCode":"300759","exchange":"sz","stockType":"company","tickerId":300759,"name":"康龙化成"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000025172,"stockId":300347,"holdings":29800,"marketCap":1604134,"netValueRatio":0.0646,"quarterlyChange":-0.050617283950616376,"stock":{"stockCode":"300347","exchange":"sz","stockType":"company","tickerId":300347,"name":"泰格医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000025172,"stockId":301201,"holdings":29300,"marketCap":1514810,"netValueRatio":0.061,"quarterlyChange":0.2702702702702695,"stock":{"stockCode":"301201","tickerId":301201,"exchange":"sz","stockType":"company","name":"诚达药业"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000025172,"stockId":688235,"holdings":6358,"marketCap":1485165,"netValueRatio":0.0598,"quarterlyChange":-0.1303425167535377,"stock":{"stockCode":"688235","tickerId":688235,"exchange":"sh","stockType":"company","name":"百济神州"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000025172,"stockId":300683,"holdings":34000,"marketCap":1474240,"netValueRatio":0.0594,"quarterlyChange":0.563649477100612,"stock":{"stockCode":"300683","exchange":"sz","stockType":"company","tickerId":300683,"name":"海特生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000025172,"stockId":2382,"holdings":141400,"marketCap":1125544,"netValueRatio":0.0453,"quarterlyChange":0.4214285714285715,"stock":{"stockCode":"002382","exchange":"sz","stockType":"company","tickerId":2382,"name":"蓝帆医疗"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000025172,"stockId":1000000000002162,"holdings":18000,"marketCap":964711,"netValueRatio":0.0388,"quarterlyChange":0.1356407857811035,"stock":{"stockType":"company","exchange":"hk","stockCode":"02162","tickerId":2162,"name":"康诺亚-B"}}]},"list":[{"_id":"69e7d5996201787ae129f5e4","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","stockId":3000000025172,"sao":"2026年一季度，整体市场仍处于行业轮动状态，A股生物医药行业（申万一级行业）表现中规中矩，一季度下跌0.90%，在31个子行业中排名14。细分赛道方面，CRO和原料药板块表现较好，而创新药和医疗器械板块虽然有短暂的亮眼表现，但整个一季度仍处于震荡回调态势。恒生医疗保健业指数单季度回调2.28%，与A股整体趋势一致。　　行业方面，一季度延续了前几个季度的趋势，创新药BD出海持续落地。根据国家药监局最新发布的数据，2026年1~3月，我国BD交易总额突破600亿美元，接近2025年1357亿美元总额的50%。这组数据传递出一个信号：国内创新药的国际认可度和供给质量已经进入一个稳定的运行轨道，BD也成为了能够为企业贡献稳定现金流的一个保障。创新药上下游产业链的景气度拐点也持续验证。　　对于后续看好的方向，我们保持2025年底的判断，把注意力集中在具有ALPHA的高景气细分领域。关注方向包括：（1）行业发展重回正轨的赛道，如 CXO 和生命科学上游资产；（2）具有技术突破机会的创新赛道，如多抗、细胞基因治疗、ADC、小核酸、脑机、AI医疗等；（3）具有市场0-1突破的潜在大单品领域。在经历过去几个月的市场调整后，生物医药的投资回归理性，虽然部分突发的地缘事件对于市场产生了冲击，但整个行业发展再次回到了相对健康的生态，生物医药行业中长期来看仍是一个值得长期布局的赛道。","lastUpdated":"2026-04-21T19:52:57.768Z","fund":{"_id":3000000025172,"__csrcFundId":15577,"stockCode":"025172","masterFundShortName":"德邦医疗创新混合发起式","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":25172,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"德邦医疗创新混合发起式A","lastUpdated":"2025-09-12T18:05:56.865Z","name":"德邦医疗创新混合型发起式证券投资基金","pinyin":"dbylcxhhxfqszqtzjj","fundCollectionId":4000050710000,"setUpAssetScale":13106857.82,"setUpDate":"2025-08-25T16:00:00.000Z","setUpShares":13106857.82,"inceptionDate":"2025-08-28T16:00:00.000Z","followedNum":3,"managers":[{"stockCode":"j101020183","stockType":"fund_manager","exchange":"fm","tickerId":252614256740,"name":"袁之渿"}]},"announcement":{"linkText":"德邦医疗创新混合型发起式证券投资基金2026年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1471828","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed40b7fea5b3eb0544127","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-01-11T16:00:00.000Z","stockId":3000000025172,"sao":"从2025Q4来看，医药生物行业表现不佳，其中医药生物（申万一级）指数单季度回调9.3%，恒生医疗保健业指数单季度回调19.3%。　　行业方面，2025Q4行业仍然延续了前几个季度的趋势——创新药BD出海持续落地，相关上下游产业链的景气度拐点也逐步验证。虽然部分地缘事件对于细分行业的情绪面产生了一定影响，但整个行业生态似乎再次回到了相对健康的发展轨迹。　　本基金成立于三季度下旬，由于行业指数处于年内高位，所以报告期内所采取的投资策略，是在控制风险的前提下，布局生物医药中的创新领域及相关上下游产业。具体来看，重点配置的方向包括：（1）行业发展重回正轨的赛道，如 CXO 和生命科学上游资产；（2）技术领先的创新型企业，从技术平台来看：多抗、细胞基因治疗、ADC、小核酸、脑机、AI医疗等都是我们关注的重点领域。在经历过去几个月的市场调整后，生物医药的投资将回归理性，在估值合理的前提下，我们将在2026年继续把注意力集中在具有ALPHA的高景气赛道，以及赛道中那些创新能力、运维能力、成长能力出众的企业。","lastUpdated":"2026-03-09T14:07:07.978Z","fund":{"_id":3000000025172,"__csrcFundId":15577,"stockCode":"025172","masterFundShortName":"德邦医疗创新混合发起式","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":25172,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"德邦医疗创新混合发起式A","lastUpdated":"2025-09-12T18:05:56.865Z","name":"德邦医疗创新混合型发起式证券投资基金","pinyin":"dbylcxhhxfqszqtzjj","fundCollectionId":4000050710000,"setUpAssetScale":13106857.82,"setUpDate":"2025-08-25T16:00:00.000Z","setUpShares":13106857.82,"inceptionDate":"2025-08-28T16:00:00.000Z","followedNum":3,"managers":[{"stockCode":"j101020183","stockType":"fund_manager","exchange":"fm","tickerId":252614256740,"name":"袁之渿"}]},"announcement":{"linkText":"德邦医疗创新混合型发起式证券投资基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1461749","linkType":"PDF","source":"csrc_pdf"}}]}